IRLAB Therapeutics AB (publ) (ST:IRLAB-A) — Stock Price

Skr1.51 SEK
▼ -0.40% today

IRLAB Therapeutics AB (publ) (ST:IRLAB-A) is currently trading at Skr1.51 SEK, down 0.40% today. Over the past 52 weeks, shares have ranged between Skr1.20 and Skr3.14. This page tracks IRLAB Therapeutics AB (publ)'s live share price on the ST exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see IRLAB-A company net worth.

IRLAB Therapeutics AB (publ) (IRLAB-A) Stock Price Chart — Daily History & Trading Volume

The chart below tracks IRLAB Therapeutics AB (publ)'s daily closing share price and trading volume on the ST exchange over the past year, giving a clear view of recent price momentum and liquidity.

IRLAB Therapeutics AB (publ) Income Statement — Revenue, Profit & Earnings by Year

IRLAB Therapeutics AB (publ)'s annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20252024202320222021
Total Revenue Skr57.46 Million Skr94.63 Million Skr5.68 Million Skr61.14 Million Skr207.78 Million
Cost of Revenue Skr149.81 Million Skr187.05 Million Skr128.41 Million Skr172.37 Million Skr39.09 Million
Gross Profit Skr-92.35 Million Skr-92.42 Million Skr-122.73 Million Skr-111.23 Million Skr168.69 Million
Research & Development Skr130.79 Million Skr163.67 Million Skr151.31 Million Skr146.18 Million Skr39.35 Million
SG&A Skr46.12 Million Skr46.18 Million Skr53.08 Million Skr125.91 Million Skr81.74 Million
Total Operating Expenses Skr150.86 Million Skr33.45 Million Skr58.03 Million Skr174.25 Million Skr116.11 Million
Operating Income Skr-92.35 Million Skr-75.11 Million Skr-180.76 Million Skr-113.11 Million Skr52.58 Million
EBITDA Skr-88.03 Million Skr-68.07 Million Skr-173.32 Million Skr-109.13 Million Skr55.79 Million
EBIT Skr-92.35 Million Skr-72.65 Million Skr-177.64 Million Skr-113.11 Million Skr52.58 Million
Interest Expense Skr17.99 Million Skr10.48 Million Skr199.00K Skr297.00K Skr370.00K
Income Before Tax Skr-110.01 Million Skr-83.13 Million Skr-177.84 Million Skr-113.41 Million Skr51.78 Million
Income Tax Expense Skr4.15 Million Skr797.00K Skr370.00K
Net Income Skr-110.01 Million Skr-83.13 Million Skr-177.84 Million Skr-114.20 Million Skr51.78 Million

IRLAB Therapeutics AB (publ) Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes IRLAB Therapeutics AB (publ)'s financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20252024202320222021
Total Assets Skr138.21 Million Skr136.21 Million Skr177.12 Million Skr323.56 Million Skr472.45 Million
Total Current Assets Skr85.87 Million Skr79.56 Million Skr123.59 Million Skr268.68 Million Skr421.44 Million
Cash & Equivalents Skr81.86 Million Skr66.92 Million Skr111.31 Million Skr252.78 Million Skr401.90 Million
Short-term Investments
Net Receivables Skr4.01 Million Skr20.63 Million Skr8.96 Million Skr12.22 Million Skr17.03 Million
Inventory Skr1.00K Skr3.69 Million Skr2.51 Million
Property, Plant & Equipment Skr5.47 Million Skr9.79 Million Skr6.67 Million Skr8.01 Million Skr8.35 Million
Goodwill
Total Liabilities Skr107.49 Million Skr103.58 Million Skr61.36 Million Skr32.72 Million Skr72.97 Million
Total Current Liabilities Skr107.49 Million Skr100.04 Million Skr36.73 Million Skr32.34 Million Skr69.40 Million
Long-term Debt Skr0.00 Skr0.00 Skr24.51 Million Skr0.00
Net Debt Skr-51.91 Million Skr-6.50 Million Skr-83.74 Million Skr-248.80 Million Skr-395.30 Million
Total Stockholder Equity Skr30.72 Million Skr32.63 Million Skr115.76 Million Skr290.83 Million Skr399.48 Million
Retained Earnings Skr-771.39 Million Skr-658.61 Million Skr-575.48 Million Skr-400.41 Million Skr-287.00 Million

IRLAB Therapeutics AB (publ) Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how IRLAB Therapeutics AB (publ) generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20252024202320222021
Operating Cash Flow Skr-55.22 Million Skr-65.59 Million Skr-164.85 Million Skr-142.61 Million Skr128.64 Million
Capital Expenditures Skr0.00 Skr199.00K Skr293.00K Skr3.38 Million Skr708.00K
Free Cash Flow Skr-55.22 Million Skr-65.79 Million Skr-165.14 Million Skr-145.99 Million Skr127.93 Million
Investing Cash Flow Skr0.00 Skr-199.00K Skr-293.00K Skr-3.38 Million Skr-708.00K
Financing Cash Flow Skr73.41 Million Skr21.40 Million Skr23.68 Million Skr-3.13 Million Skr-3.04 Million
Dividends Paid Skr3.23 Million
Stock-Based Compensation
Depreciation Skr4.32 Million Skr4.58 Million Skr4.32 Million Skr3.98 Million Skr3.47 Million
Change in Cash Skr14.94 Million Skr-44.39 Million Skr-141.47 Million Skr-149.12 Million Skr124.89 Million

IRLAB Therapeutics AB (publ) Earnings History — EPS Actual vs. Analyst Estimates

Track IRLAB Therapeutics AB (publ)'s quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
May 06, 2026
Feb 25, 2026 -0.29
Oct 29, 2025 -0.24
Aug 27, 2025 -0.62
May 06, 2025 -0.65
Feb 12, 2025 -0.10
Oct 30, 2024 -0.61
Jul 10, 2024 -0.14